The Efficacy Of Ranibizumab In The Treatment Of Macular Edema Second

Retinal vein occlusion ( RVO ) causes significant visual loss in patients with medical diseases especially systemic hypertension . Centrally involving macular edema is the main cause of loss of vision in such patients . previous treatment strategies for macular edema involve argon laser retinal photocoagulation , Radial optic neurotomy, intravitreal injections of steroids but recently the introduction of anti-vascular endothelial growth factor medications represents a breakthrough and has revolutionized the treatment of retinal vein occlusion associated macular edema in addition to the beneficial effect of suppressing the risky retinal neovascularization . Ranibizumab ( Lucentis ) is one of the most commonly used Anti-VEGF drugs in treatment of macular edema associated with retinal vein occlusion RVO whether the central type ( CRVO ) or the branch type ( BRVO ) .

Autorentext

The research book was to evaluate the efficacy of ranibizumab (Lucentis) injection in treating patients with CRVO & BRVO induced macular edemaand to compare its efficacy in ischemic versus perfused forms of RVO.RVO: Retinal Vein occlusion.CRVO: Central Retinal Vein occlusion.BRVO: Branch Retinal Vein occlusion.